Everpar Advisors LLC Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Everpar Advisors LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 890 shares of the biopharmaceutical company’s stock, valued at approximately $782,000.

Other large investors have also added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. Fortitude Family Office LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. MCF Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares in the last quarter. Criterion Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $37,000. Finally, Bruce G. Allen Investments LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $40,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded up $11.33 during trading on Tuesday, reaching $969.97. 362,317 shares of the company’s stock traded hands, compared to its average volume of 496,674. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The firm has a market cap of $106.46 billion, a PE ratio of 28.65, a P/E/G ratio of 2.74 and a beta of 0.17. The company has a 50-day simple moving average of $942.67 and a 200-day simple moving average of $899.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same period last year, the firm earned $10.96 EPS. The company’s quarterly revenue was up .6% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Insider Activity

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Marion Mccourt sold 358 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $967.50, for a total value of $346,365.00. Following the completion of the sale, the executive vice president now owns 13,431 shares in the company, valued at $12,994,492.50. The disclosure for this sale can be found here. Insiders have sold 9,095 shares of company stock worth $8,729,766 in the last ninety days. Company insiders own 8.83% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Royal Bank of Canada reissued an “outperform” rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Finally, Barclays raised their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $981.71.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.